Westside Investment Management Inc. Sells 71 Shares of Becton, Dickinson and Company (NYSE:BDX)

Westside Investment Management Inc. lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 29.8% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 167 shares of the medical instruments supplier’s stock after selling 71 shares during the period. Westside Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $41,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Ridgewood Investments LLC grew its holdings in Becton, Dickinson and Company by 1.5% during the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after purchasing an additional 43 shares during the period. Key Client Fiduciary Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 2.6% during the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after acquiring an additional 43 shares during the period. CWM LLC boosted its holdings in shares of Becton, Dickinson and Company by 0.7% during the fourth quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after acquiring an additional 46 shares during the period. S.A. Mason LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.5% during the fourth quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after acquiring an additional 48 shares during the period. Finally, Edge Capital Group LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.1% during the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 48 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BDX shares. Evercore ISI reduced their price objective on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective for the company. Barclays boosted their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Finally, StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $280.86.

View Our Latest Research Report on BDX

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares in the company, valued at $3,457,713.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock worth $2,033,381 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2 %

NYSE BDX opened at $228.84 on Friday. Becton, Dickinson and Company has a 1-year low of $224.00 and a 1-year high of $287.32. The company has a market cap of $66.14 billion, a price-to-earnings ratio of 50.41, a PEG ratio of 2.01 and a beta of 0.42. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a 50 day moving average of $234.07 and a 200-day moving average of $237.64.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the previous year, the business earned $2.86 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.66%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.